List view / Grid view
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
Administering two doses of a COVID-19 vaccine called BVX-0320 is effective in mouse models, a pre-clinical study has shown.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
Having analysed the SARS-CoV-2 genomes from over 46,723 patients, researchers have found no mutations that increase transmissibility.
A research team has shown that T-cell responses specific to SARS-CoV-2 remain in the body after infection, providing immunity from mild re-infection.
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
In pre-clinical studies, researchers have shown that a new therapy called POMHEX can destroy brain cancer cells that were missing one of two genes encoding the enolase enzyme.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
